Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06590090 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06590090 · ClinicalTrials.gov record · last posted 2025-12-09

Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment

StatusNot Yet Recruiting
PhasePhase 2
Started2026-07-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Approximately 108 subjects will be randomized in 2 arms in 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks. At the week 14 visit subjects in both arms will undergo a safety follow up visit OR begin receiving biweekly subcutaneous injections of 400mg Natrunix for 14 weeks as part of an Open Label Extension (OLE). The study will last for a maximum of 33 weeks, including: a screening period of up to 4 weeks, a 14-week double-blinded treatment phase followed by a 14-week open label extension phase and one-week follow-up.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-09-05; most recent amendment 2025-12-05. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT06590090
Lead Sponsor XBiotech, Inc.
Conditions Rheumatoid Arthritis
Enrollment 108 participants
Start Date 2026-07-15
Primary Completion 2027-01-15 (estimated)
Study Completion 2027-07-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-09